Bài viết
Chuyên mục blog về Trí tuệ Nhân tạo (AI)! Nơi chia sẽ kiến thức từ lý thuyết đến thực tế của một trong những lĩnh vực công nghệ nhanh nhất và hứa hẹn nhất của thời đại hiện đại.
Bài viết
08/01/2024 admin
The healthcare landscape is undergoing a revolutionary transformation, driven by advances in artificial intelligence (AI).
And when it comes to cancer, particularly rectal cancer, AI is proving to be a life-saving tool.
Doctors at Penn Medicine Princeton Medical Center’s (PMC) Center for Digestive Health are harnessing the power of AI to enhance the early detection of hard-to-find precancerous polyps during screening colonoscopies.
Rectal cancer stands as one of the most prevalent and preventable forms of cancer in the United States.
Alarming statistics from the American Cancer Society estimate that over 153,000 new cases of rectal cancer will be diagnosed in the U.S. this year, with nearly 53,000 fatalities attributed to the disease.
Disturbingly, the rates of rectal cancer are on the rise among individuals under the age of 55, experiencing an approximate 2% annual increase since the mid-1990s.
Most cases diagnosed in younger individuals are often in advanced stages, posing significant challenges in treatment.
While researchers delve into the causes of this surge in younger adults, several risk factors, including genetic predisposition, lifestyle choices, and inflammatory bowel diseases, contribute to rectal cancer across all age groups.
Early detection plays a pivotal role in the successful management of rectal cancer.
Typically originating as polyps or growths in the rectum, these adenomas may remain asymptomatic, making early screening crucial.
The American Cancer Society recommends regular screenings from the age of 45 for those at average risk, while individuals with a family history should commence screenings earlier, following consultation with their healthcare provider.
Moreover, it is crucial to identify and see a doctor right away when symptoms occur, which includes:
Colonoscopy remains the gold standard for detecting and preventing colon cancer. The integration of AI into this procedure marks a significant leap forward in the field of oncology.
At VinBrain, we have created DrAid™ MRI Rectal Cancer D&T, an FDA-approved AI system, for screening and surveillance colonoscopies.
In real-time, the system, guided by sophisticated algorithms, assists physicians by automatically identifying abnormal lesions. DrAid™ MRI Rectal Cancer D&T is also crucial to oncologists’, helping them prepare personalized treatment plans.
And while AI-assisted colonoscopy is trailblazing technology, it's crucial to note that the technology is designed to complement the expertise of well-trained clinicians, aiming to support their decision-making processes.
Clinical trials utilizing DrAid™ MRI Rectal Cancer D&T has shown a 70% decrease in detection time for doctors, and a 70-80% rate of survival when using AI for detection. This underscores the potential of AI in improving the efficacy of cancer screenings and ultimately saving more lives through early detection and intervention.
In addition to embracing technological advancements, individuals can actively reduce their risk of colorectal and other cancers through lifestyle modifications.
Adopting a well-balanced diet rich in fruits, vegetables, and whole grains, maintaining a healthy weight, engaging in regular physical activity, limiting alcohol consumption, and avoiding tobacco are key factors in cancer prevention. These lifestyle choices not only mitigate the risk of developing cancer but also contribute to overall well-being.
In conclusion, the integration of AI in oncology, particularly in the context of colorectal cancer screening and treatment, represents a groundbreaking advancement. By combining the power of VinBrain's DrAid™ MRI Rectal Cancer D&T with the expertise of healthcare professionals, we stand on the brink of a new era where early detection is more accurate, and treatment outcomes are optimized, offering hope for a future with fewer lives lost to colorectal cancer.